A Phase 1, Randomized, Open-Label Study to Evaluate the Effect of Cyclosporine on the Plasma Pharmacokinetics of AT-527 in Healthy Adult Male Subjects
Latest Information Update: 04 Aug 2021
Price :
$35 *
At a glance
- Drugs Bemnifosbuvir (Primary) ; Ciclosporin
- Indications COVID 2019 infections; Hepatitis C
- Focus Pharmacokinetics
- Sponsors Atea Pharmaceuticals
- 27 Jul 2021 Status changed from not yet recruiting to completed.
- 20 Apr 2021 New trial record